An observational study in Type 2 Diabetes and Healthy, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Vanderbilt University Medical Center · Observational
Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1 activation in persons with severe peripheral artery disease. We seek, through this project, to understand PAR-1 activation in persons without peripheral artery disease. As many patients with peripheral artery disease have diabetes, we will also evaluate PAR-1 activation in persons with type 2 diabetes. In addition we will assess the impact of the glucagon-like peptide (GLP)-1 signaling pathway on platelet activation. Levels of platelet activation will be determined using platelet aggregation experiments and assessment of platelet-monocyte aggregates in peripheral blood.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's enrollment of 100 is below the median of 233 across 2,218 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.
Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Type 2 diabetic and healthy subjects
Exclusion Criteria:
Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
Platelet Activation
Number of dilysyl-MDA cross-links formed in human platelets
Time frame: One day
Protease Activated Receptor-1 Activation
Number of cleaved PAR-1 receptors in proportion to number of uncleared PAR-1 receptors
Time frame: One day
Plan to share: Yes — IPD that underlie results in a publication, after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center